共 152 条
[1]
Zuo Z(2021)Survival nomogram for stage IB non-small-cell lung cancer patients, based on the SEER database and an external validation cohort Ann Surg Oncol 28 3941-3950
[2]
Zhang G(2018)Prognostic factors including lymphovascular invasion on survival for resected non-small cell lung cancer J Thorac Cardiovasc Surg 156 785-793
[3]
Song P(2014)Lymphovascular invasion as a prognostic indicator in stage I non-small cell lung cancer: a systematic review and meta-analysis Ann Thorac Surg 97 965-971
[4]
Okiror L(2022)Lobectomy offers improved survival outcomes relative to segmentectomy for >2 but ≤4 cm non-small cell lung cancer tumors JTCVS Open 10 356-367
[5]
Harling L(2018)Survival rates after lobectomy, segmentectomy, and wedge resection for non-small cell lung cancer Ann Thorac Surg 105 1483-1491
[6]
Toufektzian L(2022)Who are the real high-risk patients with pathological T2N0M0 non-small-cell lung cancer that can benefit from adjuvant chemotherapy? ESMO Open 7 5043-5051
[7]
Mollberg NM(2008)Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups J Clin Oncol 26 e41-e47
[8]
Bennette C(2017)A cost-effectiveness analysis of using the JBR.10-based 15-gene expression signature to guide adjuvant chemotherapy in early stage non-small-cell lung cancer Clin Lung Cancer 18 2256-2261
[9]
Howell E(2007)Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer–a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1187-1194
[10]
Backhus L(2016)Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis PLoS One 11 3091-3103